Apheresis is a
process wherein blood from a person (patient or donor) is passed through a
medical device to extract the required components through centrifugation or
membrane filtration technologies, and later returned to circulation with or
without extracorporeal treatment. Apheresis process is used either for donation
of blood (donor apheresis) or for therapeutic treatment (therapeutic
apheresis). Rising prevalence of blood disorders such as sickle cell anemia,
blood cancer, and hemophilia will help drive growth in demand for apheresis
equipment. Other factors driving growth in the market include escalating demand
for plasma from biopharmaceutical companies for use in plasma fractionation,
new establishment of community blood centers, and increased investments in blood
and blood component collection equipment. The growing adoption of apheresis
equipment is largely attributable to the numerous benefits offered by the
technology such as, reduced risk of allogeneic-donor exposures &
transfusion complications among recipient patients, cost efficiency, and
benefits in patient management. The growing demand for safe blood among
hospitals and patients will therefore spur growth in investments in apheresis
equipment.
The key factors
driving growth in the donor apheresis market include rising awareness over the
safety of blood donation through apheresis, and growing number of platelet
donations (Platelet Apheresis),
plasma donations (Plasma Apheresis),
leukocytes donation (Leukapheresis)
and double red cell donation, among others. Donor apheresis procedures are
growing in popularity driven by their advantages over whole blood collection.
Demand for therapeutic apheresis, on the other hand, is fuelled by the increasing
use of apheresis in the treatment of cancer and autoimmune disorders. Expanding
application of therapeutic apheresis in treating circulatory disorders caused
by excess blood proteins is also benefiting the market. In the coming years,
new avenues for therapeutic apheresis will emerge from the Pediatrics sector,
given the huge unmet medical needs among infants and children.
As stated by the new
market research report on Apheresis Equipment, the United States represents the
largest market worldwide, supported by high patient awareness, well-established
healthcare infrastructure, supportive reimbursement policies and availability of
advanced blood collection technologies. Asia-Pacific is forecast to emerge as the
fastest growing market with a projected CAGR of 12% over the analysis period. Growth
in the region is led by rising incidence of disease and sickness among the
growing population, government focus on healthcare infrastructure development, easy
access to affordable healthcare, increasing number of government licensed and
accredited blood banks, launch of numerous new voluntary blood donation camps
and higher healthcare spends among the growing base of affluent middle class
population.
Major players covered in the report include Asahi Kasei Medical Co.
Ltd., B Braun Melsungen AG, Cerus Corporation, Fresenius Kabi, Fenwal Inc.,
Haemonetics Corporation, HemaCare Corporation, Kaneka Corporation, Kawasumi
Laboratories Inc., Medica SpA, NIKKISO Europe GmbH, Terumo BCT Inc., and
Therakos Inc., among others.
The research report titled “Apheresis
Equipment: A Global Strategic Business Report”, announced by Global
Industry Analysts, Inc., provides a comprehensive review of market trends,
issues, drivers, mergers, acquisitions and other strategic industry activities.
The report provides market estimates and projections in US$ for all major
geographic markets including the US, Canada, Japan, Europe, Asia-Pacific, and
Rest of World. Product segments
analyzed in the report include Equipment for Therapeutic Apheresis and
Equipment for Donor Apheresis. Also analyzed are apheresis equipment by
procedure type including Erythrocytapheresis, Plasmapheresis, Plateletpheresis,
and Others.
Comments
Post a Comment